Design, Synthesis, and Biological Testing of Pyrazoline Derivatives of Combretastatin-A4: A Quest for Anticancer, Anti-Inflammatory, and Antioxidant Agents
{"title":"Design, Synthesis, and Biological Testing of Pyrazoline Derivatives of Combretastatin-A4: A Quest for Anticancer, Anti-Inflammatory, and Antioxidant Agents","authors":"","doi":"10.1080/10406638.2023.2271113","DOIUrl":null,"url":null,"abstract":"<div><div>Three groups of novel analogs of combretastatin-A4 (CA-4), viz., the <em>N</em><sup>1</sup>-phenyl-pyrazoline (<strong>5a–e</strong>), <em>N</em><sup>1</sup>-alkyl acetylated pyrazoline (<strong>6a–c</strong>), and <em>N</em><sup>1</sup>-phenyl acetylated pyrazoline (<strong>7a–g</strong>) were designed, and synthesized in good yield. The structure of the compounds was confirmed by spectroscopic techniques. All the compounds were evaluated for their <em>in vitro</em> anticancer (MCF-7 cell line), antioxidant (DPPH, NO, SOR, and H<sub>2</sub>O<sub>2</sub>), and anti-inflammatory activity. Compounds <strong>5d</strong>, <strong>7g</strong>, <strong>7f</strong>, <strong>7e</strong>, <strong>7c</strong>, <strong>5b</strong>, <strong>6a</strong>, <strong>7b</strong>, and <strong>7a</strong> showed excellent potency with GI<sub>50</sub> ranging from 0.1 to 10.9 µM against the MCF-7 cell line. Compounds <strong>7f</strong>, <strong>7g</strong>, <strong>5c</strong>, <strong>5d</strong>, <strong>5b</strong>, <strong>7e</strong>, and <strong>6a</strong> exhibited good anti-inflammatory activity. Encouraged by these results, all the compounds were also tested for their antioxidant potency. Compounds <strong>6a</strong>, <strong>6c</strong>, <strong>7b</strong>, <strong>7c</strong>, <strong>7f</strong>, and <strong>7g</strong> were found to be excellent scavengers of all four free radicals (DPPH, NO, SOR, and H<sub>2</sub>O<sub>2</sub>).</div></div>","PeriodicalId":20303,"journal":{"name":"Polycyclic Aromatic Compounds","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Polycyclic Aromatic Compounds","FirstCategoryId":"92","ListUrlMain":"https://www.sciencedirect.com/org/science/article/pii/S1040663823021346","RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, ORGANIC","Score":null,"Total":0}
引用次数: 0
Abstract
Three groups of novel analogs of combretastatin-A4 (CA-4), viz., the N1-phenyl-pyrazoline (5a–e), N1-alkyl acetylated pyrazoline (6a–c), and N1-phenyl acetylated pyrazoline (7a–g) were designed, and synthesized in good yield. The structure of the compounds was confirmed by spectroscopic techniques. All the compounds were evaluated for their in vitro anticancer (MCF-7 cell line), antioxidant (DPPH, NO, SOR, and H2O2), and anti-inflammatory activity. Compounds 5d, 7g, 7f, 7e, 7c, 5b, 6a, 7b, and 7a showed excellent potency with GI50 ranging from 0.1 to 10.9 µM against the MCF-7 cell line. Compounds 7f, 7g, 5c, 5d, 5b, 7e, and 6a exhibited good anti-inflammatory activity. Encouraged by these results, all the compounds were also tested for their antioxidant potency. Compounds 6a, 6c, 7b, 7c, 7f, and 7g were found to be excellent scavengers of all four free radicals (DPPH, NO, SOR, and H2O2).
期刊介绍:
The purpose of Polycyclic Aromatic Compounds is to provide an international and interdisciplinary forum for all aspects of research related to polycyclic aromatic compounds (PAC). Topics range from fundamental research in chemistry (including synthetic and theoretical chemistry) and physics (including astrophysics), as well as thermodynamics, spectroscopy, analytical methods, and biology to applied studies in environmental science, biochemistry, toxicology, and industry. Polycyclic Aromatic Compounds has an outstanding Editorial Board and offers a rapid and efficient peer review process, as well as a flexible open access policy.